/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Dr Matthew Lee is a Cardiology Clinical Senior Lecturer and Honorary Consultant Cardiologist (from 2024) at the University of Glasgow. He trained in Cardiology and General Internal Medicine in Edinburgh (2005-2012) and Glasgow (2012-2023). He was awarded the Bellahouston Medal for his PhD at the University of Glasgow (2022), based on the SUGAR-DM-HF trial. He is a CardioVascular Clinical Trialists (CVCT) Future Trialists Fellow (from 2022). His interests include clinical trials, HF, cardiomyopathies, obesity/weight loss, diabetes, pharmacotherapy (SGLT2i, GLP-1RA, cardiac myosin inhibitors), systematic review, meta-analysis, and multi-modality imaging (CMR, renal MRI, TTE, lung ultrasound). He is the co-chief investigator for BIOPEF. He serves on trial steering committees (SEQUOIA-HCM) and clinical event committees (FINEARTS-HF, REVIVED-BCIS2, CABG-ACS).
